Interpretation of biomonitoring data in clinical medicine and the exposure sciences

Toxicology and Applied Pharmacology

Volumn 233, Issue 1, 2008, Pages 76-80

  Williams, Bryan L ^a   Barr, Dana B ^b   Wright, J Michael ^c   Buckley, Brian ^d   Magsumbol, Melina S ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b NATIONAL CENTER FOR ENVIRONMENTAL HEALTH   (United States)

^c U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^d RUTGERS UNIVERSITY   (United States)

Author keywords

Biomarkers; Biomonitoring; Clinical medicine; Exposure science; Lead; Mercury; Neonatal exposures; Susceptible populations

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BIOLOGICAL MONITORING; CLINICAL MEDICINE; DATA ANALYSIS; ENVIRONMENTAL EXPOSURE; HUMAN; NONHUMAN;

BIOLOGICAL MARKERS; CLINICAL MEDICINE; DATABASES, FACTUAL; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; ENVIRONMENTAL POLLUTANTS; HUMANS;

EID: 55649087353     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2008.05.002     Document Type: Article

References (45)

1. AAP. AAP policy statement on screening, treatment and prevention of lead poisoning. Am. Fam. Phys. 48 (1993) 1161-1164
2. Anderson M.K., Amrich M., Decker K.L., and Mervis C.A. Using state lead poisoning surveillance system data to assess false positive results of capillary testing. Matern. Child Health J. 11 (2007) 603-610
3. Bahadori T., Phillips R.D., Money C.D., Quackenboss J.J., Clewell H.J., Bus J.S., Robison S.H., Humphris C.J., Parekh A.A., Osborn K., and Kauffman R.M. Making sense of human biomonitoring data: findings and recommendations of a workshop. J. Expo. Sci. Environ. Epidemiol. 17 (2007) 308-313
4. Birnbaum L.S., and Cohen Hubal E.A. Polybrominated diphenyl ethers: a case study for using biomonitoring data to address risk assessment questions. Environ. Health Perspect. 114 (2006) 1770-1775
5. Brody J.G., Morello-Frosch R., Brown P., Rudel R.A., Altman R.G., Frye M., Osimo C.A., Perez C., and Seryak L.M. Improving disclosure and consent: "is it safe?": new ethics for reporting personal exposures to environmental chemicals. Am. J. Public Health 97 (2007) 1547-1554
6. Burke T., Cullen M., Eadon G., Farmer P., Ginsberg G., Henry C., Holland N., Johanson G., Johnson B., Needham L.L., Patton D., Van Belle G., Viau C., Whyatt R., and Yang R. Human Biomonitoring for Environmental Chemicals (2005), National Academies Press, Washington, D.C.
7. Calafat A.M., Ye X., Silva M.J., Kuklenyik Z., and Needham L.L. Human exposure assessment to environmental chemicals using biomonitoring. Int. J. Androl. 29 (2006) 166-171 (discussion 181-165)
8. Centers for Disease Control and Prevention, 2005. Third National Report on Human Exposure to Environmental Chemicals. Centers for Disease Control and Prevention, Atlanta, G. A.
9. Chhabra R.S., Bucher J.R., Wolfe M., and Portier C. Toxicity characterization of environmental chemicals by the US National Toxicology Program: an overview. Int. J. Hyg. Environ. Health 206 (2003) 437-445
10. Collins C.D., Purohit S., Podolsky R.H., Zhao H.S., Schatz D., Eckenrode S.E., Yang P., Hopkins D., Muir A., Hoffman M., McIndoe R.A., Rewers M., and She J.X. The application of genomic and proteomic technologies in predictive, preventive and personalized medicine. Vasc. Pharmacol. 45 (2006) 258-267
11. De Roos A.J., Smith M.T., Chanock S., and Rothman N. Toxicological considerations in the application and interpretation of susceptibility biomarkers in epidemiological studies. IARC Sci. Publ. (2004) 105-125
12. Dietrich K.N., Ware J.H., Salganik M., Radcliffe J., Rogan W.J., Rhoads G.G., Fay M.E., Davoli C.T., Denckla M.B., Bornschein R.L., Schwarz D., Dockery D.W., Adubato S., and Jones R.L. Effect of chelation therapy on the neuropsychological and behavioral development of lead-exposed children after school entry. Pediatrics 114 (2004) 19-26
13. Fisher C.G., and Wood K.B. Introduction to and techniques of evidence-based medicine. Spine 32 (2007) S66-72
14. Fontanarosa P.B., and DeAngelis C.D. Translational medical research. JAMA 289 (2003) 2133
15. Frisch M., and Schwartz B.S. The pitfalls of hair analysis for toxicants in clinical practice: three case reports. Environ. Health Perspect. 110 (2002) 433-436
16. Gracia R.C., and Snodgrass W.R. Lead toxicity and chelation therapy. Am. J. Health Syst. Pharm. 64 (2007) 45-53
17. Grosse S.D., Matte T.D., Schwartz J., and Jackson R.J. Economic gains resulting from the reduction in children's exposure to lead in the United States. Environ. Health Perspect. 110 (2002) 563-569
18. Hays S.M., Becker R.A., Leung H.W., Aylward L.L., and Pyatt D.W. Biomonitoring equivalents: a screening approach for interpreting biomonitoring results from a public health risk perspective. Regul. Toxicol. Pharmacol. 47 (2007) 96-109
19. Ioannidis J.P. Molecular evidence-based medicine: evolution and integration of information in the genomic era. Eur. J. Clin. Invest. 37 (2007) 340-349
20. Kannel W.B. Some lessons in cardiovascular epidemiology from Framingham. Am. J. Cardiol. 37 (1976) 269-282
21. Kannel W.B., McGee D., and Gordon T. A general cardiovascular risk profile: the Framingham Study. Am. J. Cardiol. 38 (1976) 46-51
22. Landrigan P.J., Trasande L., Thorpe L.E., Gwynn C., Lioy P.J., D'Alton M.E., Lipkind H.S., Swanson J., Wadhwa P.D., Clark E.B., Rauh V.A., Perera F.P., and Susser E. The National Children's Study: a 21-year prospective study of 100,000 American children. Pediatrics 118 (2006) 2173-2186
23. Lanphear B.P., and Bearer C.F. Biomarkers in paediatric research and practice. Arch. Dis. Child. 90 (2005) 594-600
24. Lanphear B.P., Wright R.O., and Dietrich K.N. Environmental neurotoxins. Pediatr. Rev. 26 (2005) 191-197 (quiz 198)
25. Malcoe L.H., Lynch R.A., Keger M.C., and Skaggs V.J. Lead sources, behaviors, and socioeconomic factors in relation to blood lead of Native American and white children: a community-based assessment of a former mining area. Environ. Health Perspect. 10 (Suppl 2) (2002) 221-231
26. McGovern V. National Toxicology Program: landmarks and the road ahead. Environ. Health Perspect. 112 (2004) A874-878
27. McKenney J.M. Efficacy and safety of rosuvastatin in treatment of dyslipidemia. Am. J. Health-Syst. Pharm. 62 (2005) 1033-1047
28. Mink P.J., Goodman M., Barraj L.M., Imrey H., Kelsh M.A., and Yager J. Evaluation of uncontrolled confounding in studies of environmental exposures and neurobehavioral testing in children. Epidemiology 15 (2004) 385-393
29. Needham L.L., Calafat A.M., and Barr D.B. Uses and issues of biomonitoring. Int. J. Hyg. Environ. Health 210 (2007) 229-238
30. Ostermann J., Kumar V., Pence B.W., and Whetten K. Trends in HIV testing and differences between planned and actual testing in the United States, 2000-2005. Arch. Intern. Med. 167 (2007) 2128-2135
31. Ozkaynak H., Whyatt R.M., Needham L.L., Akland G., and Quackenboss J. Exposure assessment implications for the design and implementation of the National Children's Study. Environ. Health Perspect. 113 (2005) 1108-1115
32. Paustenbach D., and Galbraith D. Biomonitoring and biomarkers: exposure assessment will never be the same. Environ. Health Perspect. 114 (2006) 1143-1149
33. Pocock S.J., Smith M., and Baghurst P. Environmental lead and children's intelligence: a systematic review of the epidemiological evidence. BMJ 309 (1994) 1189-1197
34. Rico J.A., Kordas K., Lopez P., Rosado J.L., Vargas G.G., Ronquillo D., and Stoltzfus R.J. Efficacy of iron and/or zinc supplementation on cognitive performance of lead-exposed Mexican schoolchildren: a randomized, placebo-controlled trial. Pediatrics 117 (2006) e518-e527
35. Roberts R., and Stewart A.F. Personalized genomic medicine: a future prerequisite for the prevention of coronary artery disease. Am. Heart Hosp. J. 4 (2006) 222-227
36. Rosner D., and Markowitz G. The politics of lead toxicology and the devastating consequences for children. Am. J. Ind. Med. 50 (2007) 740-756
37. Rothenberg S.J., and Rothenberg J.C. Testing the dose-response specification in epidemiology: public health and policy consequences for lead. Environ. Health Perspect. 113 (2005) 1190-1195
38. Ryan P.B., Burke T.A., Cohen Hubal E.A., Cura J.J., and McKone T.E. Using biomarkers to inform cumulative risk assessment. Environ. Health Perspect. 115 (2007) 833-840
39. Schaffer S.J., and Campbell J.R. The new CDC and AAP lead poisoning prevention recommendations: consensus versus controversy. Pediatr. Ann. 23 (1994) 592-599
40. Schnaas L., Rothenberg S.J., Flores M.F., Martinez S., Hernandez C., Osorio E., Velasco S.R., and Perroni E. Reduced intellectual development in children with prenatal lead exposure. Environ. Health Perspect. Environ. Health Perspect. 114 (5) (2006) 719-797
41. Seo D., and Ginsburg G.S. Genomic medicine: bringing biomarkers to clinical medicine. Curr. Opin. Chem. Biol. 9 (2005) 381-386
42. Sung N.S., Crowley Jr. W.F., Genel M., Salber P., Sandy L., Sherwood L.M., Johnson S.B., Catanese V., Tilson H., Getz K., Larson E.L., Scheinberg D., Reece E.A., Slavkin H., Dobs A., Grebb J., Martinez R.A., Korn A., and Rimoin D. Central Challenges Facing the National Clinical Research Enterprise. JAMA 289 (2003) 1278-1287
43. Tsukahara H. Biomarkers for oxidative stress: clinical application in pediatric medicine. Curr. Med. Chem. 14 (2007) 339-351
44. West M., Ginsburg G.S., Huang A.T., and Nevins J.R. Embracing the complexity of genomic data for personalized medicine. Genome Res. 16 (2006) 559-566
45. Wong E.Y., Gohlke J., Griffith W.C., Farrow S., and Faustman E.M. Assessing the health benefits of air pollution reduction for children. Environ. Health Perspect. 112 (2004) 226-232